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Abstract Migraine is under diagnosed and suboptimally
treated in the majority of patients, and also associated with
decreased productivity in employees. The objective of this
retrospective study is to assess the antimigraine medication
useandassociatedresourceutilizationinemployedpatients.
Patients with primary diagnosis of migraine or receiving
antimigraine prescription drugs were identiﬁed from an
employer-sponsored health insurance plan in 2010. Medical
utilizationandhealthcarecostsweredeterminedfortheyear
of 2010. Generalized linear regression was applied to eval-
uate the association between health care costs and the use of
antimigraine medications by controlling covariates. Of 465
patients meeting the study criteria, nearly 30% that had
migraine diagnosis were prescribed antimigraine medica-
tions, and 20% that had migraine diagnosis were not pre-
scribed antimigraine medications. The remaining 50% were
prescribed antimigraine medications but did not have
migraine diagnosis. Patients with antimigraine medication
prescriptions showed lower frequency of emergency
department visits than those without antimigraine medica-
tion prescriptions. Regression models indicated an increase
inmigraine-relatedhealthcarecostsby86%butdecreasesin
all-cause medical costs and total health care costs by 42 and
26%, respectively, in the antimigraine medication use group
after adjusting for covariates. Employed patients experi-
enced inadequate pharmacotherapy for migraine treatment.
After controlling for covariates, antimigraine prescription
drug use was associated with lower total medical utilization
and health care costs. Further studies should investigate
patientself-reportedcareandneedstomanageheadacheand
develop effective intervention to improve patient quality of
life and productivity.
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Introduction
Migraine is a chronic condition characterized by moderate
to severe headaches. About 29.5 million Americans suffer
from migraine, with an estimated 18% of women and 6%
men directly affected [1–3]. The predominate (or primary)
age to experience migraines is between 25 and 55, which
coincides with an individual’s most active employment
period [4, 5]. Consequently, migraine-attributable mor-
bidity may adversely affect work productivity via absen-
teeism or presenteeism (compromised work productivity in
the course of daily labor) [6]. Additionally, migraine suf-
ferers may also experience compromised rest and leisure
that indirectly affects labor productivity, and directly
acerbates quality of life [7–9]. Studies suggest migraine-
related morbidity, particularly, accounts for costs incurred
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estimates between $13 billion and $17 billion [10–12].
Unfortunately, migraine is both under diagnosed and
inadequately treated in the majority of patients. One study
evaluated treatment patterns and health care use for chronic
migraine in a general population, and demonstrated 87.6%
of the patients with chronic migraine visited a health care
provider to obtain appropriate care [13]. Nearly 32% of
those patients received migraine-speciﬁc acute treatments
and just 33% were using preventive medications. Another
study considered migraineurs’ current patterns of health
care use, and noted 48% of migraine suffers had seen a
doctor for headache within the past year, 31% had never
done so in their lifetimes, and 21% had not seen a doctor
for headache for at least 1 year [1]. Of all the patients with
migraine, 23% were treated with prescription drugs, and
only 49% with over-the-counter medications only. Thus,
previous studies suggest a care gap exists relative to evi-
dence-based care strategies, and subsequent application in
migraine management.
Although proper diagnosis is essential to optimal
migraine management, increased burden may also be
attributed to inadequate prescription drug therapy. Studies
demonstrated improved medication use is associated with
better clinical and economic outcomes in patients with
chronic diseases. Speciﬁcally, unsustained statin use com-
promises beneﬁts, such as reduced CHD risk, and creates
substantial treatment costs attributed to otherwise pre-
ventable CHD events [14–17]. Balkrishnan’s study also
found a strong association between decreased antidiabetic
medication use and increased health care service utilization
in elderly with type 2 diabetes [18]. Currently, many
studies on migraine and associated outcomes rely upon
data gleaned via patient self-report surveys [1, 13, 19–21].
Knowledge of migraine-associated health outcomes in
patients enrolled in employer-sponsored health insurance
programs is very limited. Insights gleaned from a popula-
tion having a common baseline of assured care access may
help clarify where and how suboptimal patient outcomes
persist. It is unclear whether there is a relationship between
migraine medication use and total medical utilization and
costs, especially in employed patients. Clarifying this
relationship may elucidate the impact of explicit chronicity
on total medical costs, and subsequently clarify compre-
hensive care coordination opportunities. Health care
administrative data is a readily available source of
employees’ health care resource utilization, and may
inform insights regarding clinical and economic outcomes.
This study was designed to answer the following two pri-
mary questions: (1) What is the antimigraine prescription
drug use pattern in patients enrolled in an employer-
sponsored health plan? (2) How do the resource utilization
and health care costs differ between patients receiving
prescription drugs to treat migraine and those not receiving
prescription drugs?
Methods
Data source and patient selection
De-identiﬁed claims data based on an employer-sponsored
health plan were extracted by Advisory Board Company in
Washington D.C. All patients with at least one primary
diagnosis of migraine between January 1, 2010 and
December 31, 2010 were identiﬁed by International Clas-
siﬁcation of Diseases, 9th revision (ICD-9) (346.xx). All
patients receiving at least one prescription for a medication
to treat migraine between January 1, 2010 and December
31, 2010 were also identiﬁed by therapeutic category in the
database (Table 1). Patients were required to be enrolled in
the employer-sponsored health plan continuously during
the year of 2010. Patients enrolled as dependents were
excluded from the study. Given the bidirectional inﬂuence
of migraine and major depression described in previous
studies [22, 23], we considered comorbid depression if
patients presented at least one primary diagnosis of major
depression or received at least one prescription for an
antidepressant or antianxiety medication shown in Table 1
during the study period. All eligible patients were divided
into two groups: patients who received antimigraine med-
ications and those who did not.
Medical utilization
Total medical utilization with any conditions within 1 year
was evaluated by hospitalization frequency, emergency
department (ED) visits, and total numbers of outpatient and
physician ofﬁce visits. Patients with at least one time
hospitalization or ED visit during the study period were
categorized as hospitalization or ED visit during the study
period. Medical utilization related to migraine was identi-
ﬁed by primary diagnosis codes (346.xx).
Health care costs
Health care costs were evaluated based on third party payer
perspective. Reimbursement rates paid by the employer
were used to compute annual total and migraine-related
health care costs, including medical care and pharmacy
costs. Medical care costs were deﬁned as the sum of
inpatient, ED, hospital outpatient, and physician ofﬁce visit
costs. Annual total health care costs were the sum of
medical and pharmacy costs associated with any conditions
during the 1-year study period. Migraine-related health
care costs were identiﬁed by primary diagnosis code of
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123migraine (346.xx) for medical care costs and by prescrip-
tion drugs to treat migraine for pharmacy costs. Total
migraine-related health care costs were the sum of
migraine-related medical and pharmacy costs during the
1-year study period.
Risk index (RI) and Care gap index (CGI) [24]
RI is an index value created by using D2Hawkeye risk
modeling system to indicate the risk a member will become
a catastrophic case, and is based on the number of
comorbidities presented. Similarly, CGI is an index value
indicating the degree to which a member complies with
recommended care guidelines associated with their age and
existing conditions. Both of these scores provided by the
health insurance program are routinely used by a number of
care management program directors and managers to
identify speciﬁc patient groups that may particularly ben-
eﬁt from tailored care management programs. These two
variables were included in our regression models as
covariates for adjustment.
Data analysis
Univariate analyses were used to compare patient charac-
teristics, unadjusted medical utilization, and health care
costs between the two groups, namely, those using antim-
igraine medications and those not using antimigraine
medications. Chi-square tests were applied to analyze
categorical variables and t tests were used for continuous
variables. Nonparametric tests (Wilcoxon rank-sum test)
were used to compare various health care costs between
two groups.
Generalized linear regressions with log link and gamma
distribution were considered to analyze the associations
between health care costs and the use of antimigraine
medications after adjusting for diagnosis of migraine, age,
gender, comorbid depression, CGI, and RI. The level of
signiﬁcance was preset at a = 0.05. All statistical analyses
were conducted by SAS 9.2 (SAS Institute, Cary, NC).
Results
Figure 1 and Table 2 display the patient selection and
characteristics of our study population enrolled in an
employer-sponsored health plan during the study period
(January 1, 2011 to December 31, 2011). A total of 465
patients (5.9% of total employees enrolled in the employer-
sponsored health insurance plan in 2010) met the study
inclusion and exclusion criteria, with an average age of
43.5 years. Females accounted for nearly 95% of the study
population; two-thirds of the patients had depression
diagnosis or used antidepressants during the study period.
Of the patients receiving antimigraine medications, 64%
did not have migraine diagnosis. In contrast, 43% of
patients diagnosed with migraines, did not take antimi-
graine medications.
Table 3 compared unadjusted medical utilization and
health care costs between patients using and not using
antimigraine medications. Patients receiving antimigraine
medications evidenced 12.3 and 7.2% fewer all-cause and
migraine-related ED visits, respectively, as compared to
Table 1 Medications for migraine and depression used by
participants
Antimigraine medications Antidepressants
Acetaminophen/caffeine/
isometheptene mucate
Alprazolam
Acetaminophen/dichloralphenazone/
isometheptene mucate
Alprazolam extended-
release
Almotriptan malate Amitriptyline hydrochloride
Dihydroergotamine mesylate Amitriptyline-
chlordiazepoxide
Eletriptan hydrobromide Budeprion hydrochloride
Ergotamine-caffeine Budeprion hydrochloride
extended-release
Frovatriptan succinate Budeprion hydrochloride
sustained-release
Naratriptan hydrochloride Citalopram hydrobromide
Rizatriptan benzoate Clomipramine
hydrochloride
Sumatriptan succinate Clorazepate dipotassium
Sumatriptan succinate/naproxen
sodium
Desipramine hydrochloride
Zolmitriptan Desvenlafaxine succinate
Diazepam
Doxepin hydrochloride
Duloxetine hydrochloride
Escitalopram oxalate
Fluoxetine hydrochloride
Fluoxetine hydrochloride/
olanzapine
Fluoxetine pamoate
Imipramine hydrochloride
Lorazepam
Mirtazapine
Nortriptyline hydrochloride
Oxazepam
Paroxetine hydrochloride
Paroxetine mesylate
Phenelzine sulfate
Trazodone hydrochloride
Venlafaxine hydrochloride
Venlafaxine hydrochloride
extended-release
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123those not receiving antimigraine medications. Groups using
antimigraine medication also evidenced fewer outpatient
and ofﬁce visits. Pharmacy cost for antimigraine medica-
tion use accounted for 78% of total migraine-related costs.
An increase in all-cause pharmacy cost by $1,010 and
decrease in all-cause medical cost by $3,407 were shown in
the antimigraine medication use group.
Table 4presentsassociationsbetweenvarioushealthcare
costs and the use of migraine medications after adjusting for
diagnosis of migraine, age, gender, CGI, RI, and comorbid
depression. After translating the log-transformed coefﬁ-
cients based on generalized linear regressions, we found
even though patients receiving antimigraine medications
showedincreasedmigraine-relatedhealthcarecostsby86%,
all-cause medical costs and total health care costs were
reduced signiﬁcantly by 42 and 26%, respectively, when all
the other covariates remained constant.
Discussion
The purpose of this study was to evaluate the use pattern of
migraine prescription drugs and its effect on the health care
costs in patients enrolled in an employer-based health care
program. Our study results indicated that nearly 45% of the
patients with diagnosis of migraine did not receive appro-
priate pharmacotherapy and that nearly 65% of the patients
who received antimigraine medications did not have
migraine diagnosis. This study also found that migraine
medication costs were the major proportion of migraine-
related costs in patients, but total cost saving was shown in
the patients due to signiﬁcantly decreased medical costs.
These ﬁndings may underscore the importance of
improving current evidence-supported strategies (such as
appropriate pharmacotherapy and prophylactic regimens)
and incorporating adjunct interventions, such as patient
self-management. These efforts may improve the quality of
life and productivity in employed patients with migraine.
Pharmacotherapy, especially the triptan drug class,
accounts for the most direct costs relative to migraine care;
given the expense, it is critical to appropriately administer
and facilitate optimal use. Clouse’s study compared health
care use and associated costs in patients with migraine and
patients without migraine in a managed-care organization.
Clouse’s study [25] indicates patients with migraine had
greater morbidity in general, and incurred 64% greater
costs in health care resource use as compared with patients
without migraine. Thus, migraine medication prescription
and use may mitigate total health care costs, and have
favorable implications for the third party payers. This
ﬁnding may underscore the signiﬁcance of our ﬁndings, as
increased pharmacy cost resulting from antimigraine
medications may by justiﬁed by total medical care cost
reduction in patients with migraine (after adjusting for
covariates).
Patients report headache as one of the most commonly
reported reasons for ED visits [26, 27]. These visits may
represent an annual cost ranging from $600 million to
nearly $2 billion [12]. Our study also revealed that the
percentage of patients with at least one migraine-related or
all-cause ED visit was 7.4 or 12.3% lower in the patients
using antimigraine medications than those not using
antimigraine medications. Thus, lower medical utilization
and costs could be expected in patients subsequent to
medication initiation. In addition, using agents for migraine
prophylaxis might be considered to manage the disease and
control medical costs. Migraine prophylaxis is aimed at
preventing frequent attacks, including migraine severity
and length that often incurs high costs for pain relief,
diagnostic services, and medical care. Wertz et al. [28]
reported that headache-related resource utilization and
costs were signiﬁcantly lowered after initiation of pre-
ventive migraine treatment in a sample of a large managed-
care population. Therefore, appropriate preventive therapy
may reduce the disease burden and medical utilization.
Our study also suggests suboptimal migraine therapy,
which is consistent with previous report. Among patients
with migraine diagnosis, only 57% took antimigraine
medications. Notably, although pharmacy cost was reduced
without taking prescription drugs, total health care costs
were increased due to heavy costs on medical utilization.
Table 3 showed that those not using antimigraine drugs
presented higher frequency of ED visits and total number
of outpatient visits related to migraine. These results sug-
gested that poor health outcomes and disease management
Total number of employees enrolled in the health plan 2010 (n = 7878) 
Females (n = 6245), males (n= 1633) 
Total number of employees with at least 1 medical claim for primary 
diagnosis of migraine or at least 1 pharmacy claims for an antimigraine 
medication (n = 465) 
Antimigraine 
prescription drug 
users with 
primary diagnosis 
of migraine  
(n = 133) 
Antimigraine 
prescription drug 
users without 
primary diagnosis 
of migraine 
(n = 232)  
Antimigraine prescription 
drug users in 2010 (n = 365) 
No antimigraine prescription 
drug users in 2010 (n = 100) 
No antimigraine 
prescription drug 
users with primary 
diagnosis of migraine  
(n = 100) 
Fig. 1 Patient selection from an employer-sponsored health insur-
ance plan in 2010
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123might be associated with inadequate antimigraine medi-
cation use. Based on this evidence, there is a need to
improve the quality of migraine care, and particularly
provide physicians and patients with therapeutic options
that are effective and well tolerated. Moreover, we also
found that two-thirds of all patients in the study has
Table 2 Characteristics of the study population (n = 465)
Variable All patients
(n = 465)
Antimigraine
drug users (n = 365)
No antimigraine
drug users (n = 100)
p value
Age (years), mean (SD) 43.5 (10.9) 43.8 (10.9) 42.3 (11.0) 0.210
Gender female, n (%) 433 (93.1) 338 (92.6) 95 (95.0) 0.402
CGI, mean (SD) 2.4 (2.3) 2.4 (2.3) 2.7 (2.2) 0.150
RI, mean (SD) 17.6 (10.5) 17.7 (10.3) 17.5 (11.3) 0.861
Depression, n (%) 307 (66.0) 240 (65.8) 67 (67.0) 0.816
Diagnosis of migraine, n (%) 233 (50.1) 133 (36.4) 100 (100)
a \0.001
CGI care gap index, RI risk index, SD standard deviation
a Patients who neither used antimigraine drugs nor had migraine diagnosis were not included in the study
Table 3 Medical utilization
and health care costs of the
study population by
antimigraine medication use
(n = 465)
ED emergency department,
SD standard deviation
Variable Antimigraine drug
users (n = 365)
No antimigraine
drug users (n = 100)
p value
All-cause medical utilization
Hospitalization, n (%) 39 (10.7) 15 (15.0) 0.233
ED visits, n (%) 83 (22.7) 35 (35.0) 0.013
Total number of outpatient visits, mean (SD) 13.2 (11.9) 15.3 (15.6) 0.220
Migraine-related medical utilization
Hospitalization, n (%) 0 3 (3.0) \0.001
ED visits, n (%) 14 (3.8) 11 (11.0) 0.005
Total number of outpatient visits, mean (SD) 0.8 (1.8) 1.4 (1.2) \0.001
All-cause health care costs ($), mean (median)
Medical 7,043.7 (1921.4) 10,450.6 (3352.0) 0.019
Pharmacy 2,827.5 (1408.1) 1,817.3 (753.1) \0.001
Total 9,871.2 (4648.1) 12,267.9 (5267.3) 0.633
Migraine-related costs ($), mean (median)
Medical 149.3 (0) 634.1 (100.3) \0.001
Pharmacy 516.1 (201.9) 0 \0.001
Total 665.4 (283.5) 634.1 (100.3) 0.001
Table 4 Associations between health care costs and the use of antimigraine medications
Independent variables Estimated coefﬁcient (SE)
Dependent variable: log
(total all-cause health care costs)
Dependent variable: log
(all-cause medical costs)
Dependent variable: log
(total migraine-related costs)
Antimigraine medication use (yes vs. no) -0.30 (0.12)** -0.55 (0.17)*** 0.62 (0.18)***
Diagnosis of migraine (yes vs. no) -0.30 (0.10)** -0.37 (0.14)** 1.17 (0.15)***
Age (years) -0.01 (0.28)* -0.02 (0.01)** 0.02 (0.01)**
Gender (female vs. male) 0.21 (0.18) 0.17 (0.23) -0.15 (0.25)
CGI 0.05 (0.02)* 0.05 (0.03) 0.05 (0.03)
RI 0.08 (0.01)*** 0.08 (0.01)*** 0.01 (0.01)
Comorbid depression (yes vs. no) 0.15 (0.10) 0.19 (0.13) 0.04 (0.14)
CGI care gap index, RI risk index, SE standard error
*p\0.05, ** p\0.01, *** p\0.001
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123depression diagnosis or used antidepressant medications.
Studies showed that depression and migraine are highly
correlated and might be bidirectional. That is, migraine
may cause psychiatric conditions, vice versa or both
[23, 29]. Both of the diseases signiﬁcantly decrease health-
related quality of life [8]. Thus, assessing depressive dis-
orders in migraine patients may augment migraine care
quality.
These ﬁndings, derived from employer-sponsored claims
data, suggested antimigraine medication use may be asso-
ciated with reduced total medical utilization and health care
costs. The study results indicate opportunities to understand
self-reported care and needs of employees with headache.
We may further investigate migraineurs’ quality of lives
and productivity via survey tools. Informed by the results of
this study, we may develop intervention strategies to miti-
gate both direct (health care plan costs) and indirect (loss
productivity and absenteeism) cost. More importantly, our
results indicate a manner to improve migraine care, thereby
increasing employees’ the quality of care via treatment
optimization and targeted implementation.
Although this study provides evidence regarding the
associations among antimigraine medication use, diagnosis
of migraine, and resource utilization, we concede some
study limitations. First, the retrospective cross-sectional
study design restricts the ability to establish causal infer-
ences related to antimigraine medication use. Second, some
of these patients could use over-the-counter (OTC) medi-
cations instead of prescription drugs to manage the head-
ache, subsequently biasing our claims-based analyses.
Additionally, some patients receiving antimigraine medi-
cations without migraine diagnosis code could occur in the
administrative data. Third, we used a diagnosis of depres-
sion or antidepressant medication use as a comorbid
depression. It is possible that some of these patients
received antidepressant agents for the treatment of condi-
tions other than depression. Finally, the claims data provide
information on prescribing patterns only rather than on
actual medication use. Therefore, we suggest further
investigations include patient self-reported medication use
using a survey tool.
Conclusions
Noted limitations notwithstanding, the study results sug-
gest inadequate pharmacotherapy in migraine treatment.
After controlling for covariates, antimigraine prescription
drug use was associated with lower total medical utilization
and health care costs. This suggests appropriately manag-
ing a speciﬁc chronicity, potentially inﬂating disease-
speciﬁc expenditures, can favorably impact total health
care costs. Further studies should investigate patient
self-reported care and needs to manage headache and
develop effective intervention to improve patient quality of
life and productivity.
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